290 results on '"de Nully Brown, Peter"'
Search Results
2. Sexual health and testosterone concentration in male lymphoma survivors: A systematic review
3. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features
4. The Genetic Profile of Large B-Cell Lymphomas Presenting in the Ocular Adnexa
5. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognoses and targetable genetic features
6. Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
7. Men treated with BEACOPP for Hodgkin lymphoma may be at increased risk of testosterone deficiency
8. Social inequality in cancer survivorship: Educational differences in health‐related quality of life among 27,857 cancer survivors in Denmark
9. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
10. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
11. Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
12. Sexual dysfunction is highly prevalent in male survivors of malignant lymphoma
13. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy
14. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP (−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group
15. P074: Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study
16. An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
17. Outcome of limited‐stage peripheral T‐Cell lymphoma after CHOP(−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
18. Mental health among patients with non‐Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators
19. Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors
20. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
21. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study
22. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish–Canadian study of 443 patients with diffuse-large B-cell lymphoma
23. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients
24. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait
25. Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)
26. Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome
27. Idelalisib in relapsed/refractory diffuse large B‐cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
28. Reasons for treating secondary AML as de novo AML
29. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
30. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas
31. Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors : A population-based cohort study from Sweden and Denmark
32. Feasibility, efficacy and safety of CHOP-14 in elderly patients with very high-risk diffuse large B-cell lymphoma
33. Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Study
34. Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders
35. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera
36. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
37. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area
38. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
39. A PHASE IB, OPEN LABEL, MULTICENTER TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20-POSITIVE TUMORS, RITUXIMAB (PREBEN) IN RELAPSED AGGRESSIVE LYMPHOMAS OF B- OR T-CELL PHENOTYPE
40. Distribution of hospital care among pediatric and young adult Hodgkin lymphoma survivors—A population‐based cohort study from Sweden and Denmark
41. Prediagnosis cardiovascular risk and subsequent myocardial infarction (MI) among lymphoma survivors.
42. Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study
43. Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study
44. Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas
45. Lymphoma Patients Treated without Anthracyclines Have Negligible Risk of Cardiotoxicity: A Nationwide Cohort Study
46. The Danish National Multiple Myeloma Registry
47. Danish National Lymphoma Registry
48. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI
49. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors
50. An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.